Weight loss strategy that is 5 times more effective than Ozempic, as per study

Imagine a weight-loss strategy that, over two years, delivers five times the reduction in body weight compared with Ozempic, one of the world’s most talked-about medications. That is what a real-world comparative analysis presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting suggests and it is turning heads in the obesity-treatment world.

The finding is not about a new miracle drug, it is about the long-established metabolic and bariatric surgery procedures, such as sleeve gastrectomy and gastric bypass, outperforming injectable therapies like Ozempic (semaglutide) and Mounjaro (tirzepatide) over extended follow-up. Read on as we unpack what this really means in the context of modern weight-loss science, including how medications compare, and where other strategies stack up.

What the new research found: Surgery vs GLP-1 drugs

The recent analysis pooled real-world electronic medical records from NYU Langone Health and NYC Health + Hospitals to compare:

• People who had bariatric surgery
• People prescribed GLP-1 receptor agonist drugs (like Ozempic or tirzepatide)

After two years, patients who underwent surgery lost about five times more weight, roughly 58 pounds (≈26 kg) compared with approximately 12 pounds (≈5.3 kg) for those using GLP-1 medications.

That is a striking gap and reflects not only the intensity of surgical weight-loss mechanisms or mechanically reducing stomach size and altering gut hormone signalling but also how people use medications in real life, where adherence sometimes drops over time.

Why this matters

This is not to say that medications like Ozempic don’t work, they do produce meaningful weight loss in clinical settings but in real-world practice, up to 70% of patients discontinue GLP-1 therapy within a year, diminishing long-term effectiveness.

Surgery produces larger and sustained weight loss. According to the 2025 systematic review published in American Society for Metabolic & Bariatric Surgery Reports, “Bariatric surgery provides the most significant and enduring weight loss compared to treatments with GLP-1 receptor agonists and lifestyle changes, maintaining about 25% weight loss for up to 10 years.” This systematic evidence shows that surgery is not only more effective than drugs like Ozempic but also more durable, helping patients keep weight off for longer periods without reliance on continuous medication.

Mounjaro (Tirzepatide) often outperforms Ozempic in drug comparisons. Another 2025 study in New England Journal of Medicine found that treatment with tirzepatide was superior to semaglutide with respect to reduction in body weight and waist circumference. While still a drug-based intervention, tirzepatide (marketed as Mounjaro or Zepbound) has demonstrated greater effectiveness than semaglutide (Ozempic) in clinical trials, with participants losing significantly more weight and waist circumference over time. This highlights that not all GLP-1 agents are equal and the next-generation therapies can nudge drug performance upward, even if they still don’t match surgery’s effects in the long term.

A 2024 study in Journal of Clinical Endocrinology & Metabolism revealed that bariatric procedures alter hunger and satiety hormones, including ghrelin and GLP-1, while also modifying gut microbiota and bile acid signalling, which collectively contribute to sustained weight loss. Weight-loss surgery is effective not just because it restricts food intake but because it rewires hormonal and metabolic responses in the body, creating a more profound and sustainable shift in appetite, glucose metabolism and energy balance.

Why people turn to medications like Ozempic

Drugs such as Ozempic, Wegovy and tirzepatide were originally developed for type 2 diabetes. They mimic gut hormones (GLP-1 and GIP) that slow digestion, reduce appetite and improve blood sugar regulation. Many patients find that these drugs do produce clinically meaningful weight loss, especially at higher doses and in controlled settings.

However, real-world use tells a different story as many people stop injections over time, reducing long-term efficacy. Meanwhile, side effects (nausea, muscle loss, etc.) and cost limit adoption for some, drive continued interest in surgical and next-generation pharmacological strategies.

So is this really 5 times better than Ozempic?

In a real-world practical sense, yes. In the referenced analysis, bariatric surgery produced roughly five times the weight loss seen with GLP-1 drugs like Ozempic or tirzepatide over two years but it is important to interpret these findings carefully. Medications do work and remain valuable tools, especially for people who are not candidates for surgery.

Surgery’s effectiveness comes with trade-offs as it is invasive, requires lifestyle adjustment and carries surgical risk. Next-generation drugs and combinations may further narrow the gap by improving effectiveness with fewer side effects.

Bottom line

If you are considering weight-loss strategies, it is not about a single “miracle” option. Instead, each approach whether medication, surgery or lifestyle change, has a role and the best choice depends on your health profile, goals and medical supervision.

What this study highlights is simple but powerful. Long-term outcomes matter. In the real world, bariatric surgery remains a benchmark for sustained and substantial weight loss, even outperforming some of the most popular modern medications like Ozempic when followed over years.

Note: The information provided in this article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any new medication or treatment and before changing your diet or supplement regimen.